Withdrawals due to adverse events · Induction of Remission in Medically Refractory Crohn's Disease
It is very uncertain whether summary of findings table ‐ Stem Cell changes withdrawal due to adverse events compared with placebo or Control (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · patients with maintenance of medically‐induced remission in Crohn's disease
5‐ASA showed no clear difference in withdrawals due to adverse events compared with placebo (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · people with inflammatory bowel disease
1 finding from 1 review
Withdrawals due to adverse events · people with inflammatory bowel disease
1 finding from 1 review
Withdrawals due to adverse events · Participants with Crohn's disease in remission
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Withdrawals due to adverse events · active EoE patients
1 finding from 1 review
Withdrawals due to adverse events · active EoE pediatric patients
It is very uncertain whether one‐food elimination diet changes withdrawals due to adverse events compared with six‐food elimination diet (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · Patients with active Crohn's disease
Infliximab 5 mg/kg showed no clear difference in withdrawals due to adverse events compared with purine analogues (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · Patients with active Crohn's disease
The review found no eligible studies for this question.
2 findings from 1 review
Withdrawals due to adverse events · Patients with active Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Withdrawals due to adverse events · Patients with active Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Withdrawals due to adverse events · Patients with active Crohn's disease
Infliximab 5 mg/kg showed no clear difference in withdrawals due to adverse events compared with CT‐P13 biosimilar 5 mg/kg (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · Patients with active Crohn's disease
The review found no eligible studies for this question.
2 findings from 1 review
Withdrawals due to adverse events · active EoE pediatric patients
It is very uncertain whether mepolizumab 10 mg/kg changes withdrawals due to adverse events at 8 weeks compared with mepolizumab 0.55 mg/kg (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · active EoE pediatric patients
It is very uncertain whether mepolizumab 2.5 mg/kg changes withdrawals due to adverse events at 8 weeks compared with mepolizumab 0.55 mg/kg (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · active EoE pediatric patients
It is very uncertain whether mepolizumab 10 mg/kg changes withdrawals due to adverse events at 8 weeks compared with mepolizumab 2.5 mg/kg (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · active EoE pediatric patients
Cromolyn sodium showed no clear difference in withdrawals due to adverse events at 8 weeks compared with placebo (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · active EoE pediatric patients
It is very uncertain whether swallowed fluticasone changes withdrawals due to adverse events at 4 weeks compared with oral prednisone (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · active EoE patients
Oral viscous budesonide showed no clear difference in withdrawals due to adverse events at 8 weeks compared with swallowed fluticasone (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · active EoE patients
It is very uncertain whether esomeprazole changes withdrawals due to adverse events at 8 weeks compared with fluticasone (very low certainty).
1 finding from 1 review